FDA Approval Alert: The Need-to-Know | Zanidatamab in Metastatic HER2-Positive Biliary Tract Cancer
In November 2024, the FDA approved zanidatamab-hrii as a 50 mg/mL injection or intravenous infusion for patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer as detected by an FDA-approved test.
